Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of two doses of Nefecon versus placebo in primary IgA nephropathy
NL-OMON39659Phase 2Active, not recruiting
- Sponsor
- PharmaLink
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nefecon in IgA nephropathy (IgAN) (3 arms), sponsored by PharmaLink. Primary endpoint: Mean reduction in UPCR at 9 months. Started Jul 2013; status: active, not recruiting.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON39659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39659.